{"filing":{"accession_number":"0001213900-26-081377","cik":"0001497253","ticker":"VIVS","company_name":"VivoSim Labs, INC.","form":"8-K","filing_date":"2026-07-24","report_date":"2026-07-20","primary_document":"ea0299224-8k_vivo.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1497253/000121390026081377/ea0299224-8k_vivo.htm"},"events":[{"id":20431,"run_id":18391,"accession_number":"0001213900-26-081377","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"summary":"VivoSim Labs received a written notice from Nasdaq on July 20, 2026, indicating failure to meet the minimum $2,500,000 stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1). The company has 45 days to submit a compliance plan and faces potential delisting if compliance is not regained within 180 days.","company_name":"VivoSim Labs, INC.","ticker":"VIVS","filing_date":"2026-07-24","form":"8-K","submitted_at":null,"items":[{"id":19791,"accession_number":"0001213900-26-081377","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"VivoSim Labs received a written notice from Nasdaq on July 20, 2026, indicating failure to meet the minimum $2,500,000 stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1). The company has 45 days to submit a compliance plan and faces potential delisting if the plan is not accepted or compliance is not regained within 180 days. This is a direct delisting-risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-24T20:09:03.270121+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":20432,"run_id":18391,"accession_number":"0001213900-26-081377","anchor_item_number":"8.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"VivoSim Labs closed a private placement on July 17, 2026, issuing pre-funded warrants and common warrants to purchase approximately 4.7 million shares of common stock for gross proceeds of $4.0 million.","company_name":"VivoSim Labs, INC.","ticker":"VIVS","filing_date":"2026-07-24","form":"8-K","submitted_at":null,"items":[{"id":19792,"accession_number":"0001213900-26-081377","item_number":"8.01","item_title":"Other Information.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a private placement transaction closed on July 17, 2026, in which VivoSim Labs issued pre-funded warrants and common warrants to purchase approximately 4.7 million shares of common stock for gross proceeds of $4.0 million. This is a classic dilutive equity issuance. While the filing also mentions a $5.0 million milestone payment from Eli Lilly and warrant exercises that increased stockholders' equity, the primary disclosed transaction is the unregistered private placement of warrants, which is material to investors assessing capital structure and dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-24T20:09:03.270121+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":19791,"accession_number":"0001213900-26-081377","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"VivoSim Labs received a written notice from Nasdaq on July 20, 2026, indicating failure to meet the minimum $2,500,000 stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1). The company has 45 days to submit a compliance plan and faces potential delisting if the plan is not accepted or compliance is not regained within 180 days. This is a direct delisting-risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-24T20:09:03.270121+00:00","company_name":"VivoSim Labs, INC.","ticker":"VIVS","filing_date":"2026-07-24"},{"id":19792,"accession_number":"0001213900-26-081377","item_number":"8.01","item_title":"Other Information.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a private placement transaction closed on July 17, 2026, in which VivoSim Labs issued pre-funded warrants and common warrants to purchase approximately 4.7 million shares of common stock for gross proceeds of $4.0 million. This is a classic dilutive equity issuance. While the filing also mentions a $5.0 million milestone payment from Eli Lilly and warrant exercises that increased stockholders' equity, the primary disclosed transaction is the unregistered private placement of warrants, which is material to investors assessing capital structure and dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-24T20:09:03.270121+00:00","company_name":"VivoSim Labs, INC.","ticker":"VIVS","filing_date":"2026-07-24"}]}